Global Optic Atrophy Management Market 2024 - By Share, Size, Growth Analysis And Forecast To 2033

The new report published by The Business Research Company, titled ""Optic Atrophy Management Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the optic atrophy management market size has grown strongly in recent years. It will grow from $7.65 billion in 2023 to $8.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The optic atrophy management market size is expected to see strong growth in the next few years. It will grow to $10.91 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13499&type=smp

Anticipated Surge In Glaucoma Cases Drives Optic Atrophy Management Market Growth
An increase in the incidence of glaucoma is expected to propel the growth of the optic atrophy management market going forward. Glaucoma refers to a group of eye conditions characterized by increased intraocular pressure (pressure within the eye) that can damage the optic nerve, potentially leading to vision loss or blindness if left untreated. The projected increase in glaucoma cases is a primary catalyst for the growth of optic atrophy management, underscoring the importance of effective prevention and management strategies to reduce the risk of optic atrophy and enhance the quality of life for those affected. For instance, in October 2022, According to the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, there are currently 80 million individuals with glaucoma across the globe, with a projected increase to more than 111 million by the year 2040. Therefore, the increase in the incidence of glaucoma will drive the growth of the optic atrophy management market.

Pioneer Precision Medicine And A Gene-Based Optic Atrophy Treatment Trial
Major companies operating in the optic atrophy management market are increasing their focus on conducting trials to develop targeted therapies for rare genetic disorders and gain a competitive edge. Targeted therapies for rare genetic disorders seek to tackle the fundamental genetic origin of the condition. This involves the transfer of genetic material into cells to rectify or substitute a faulty gene, addressing the root cause of the disease. For instance, in April 2023, Stoke Therapeutics, Inc., a US-based biotechnology company, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for its clinical trial application to initiate the Phase I/II OSPREY trial of STK-002. This trial aims to treat autosomal dominant optic atrophy (ADOA), which is the most prevalent inherited optic nerve disorder causing progressive and irreversible vision loss in both eyes, typically beginning in the first decade of life. Notably, there are currently no approved treatments for this condition, and STK-002 therapy is expected to decelerate or potentially stop the progression of vision loss in individuals affected by autosomal dominant optic atrophy (ADOA).

The optic atrophy management market covered in this report is segmented -

1) By Drug Type: Disulfiram, Amebicides, Ethambutol, Isoniazid, Chloramphenicol, Vincristine, Ciclosporin, Cimetidine
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13499&type=discount

Major companies operating in the optic atrophy management market report are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline plc, Eli Lilly And Company, Boehringer Ingelheim International GmbH., Teva Pharmaceuticals, Viatris (Mylan N.V.), Astellas Pharma Inc, Bausch Health Companies Inc., Sumitomo Dainippon Pharma Co. Ltd, Bausch And Lomb Inc., Aurobindo Pharma, Cipla Ltd, Apotex Inc. , Zydus Cadila, Santen Pharmaceutical Co. Ltd, Lupin, Allergan ple., LEO Pharma A/S, Aerie Pharmaceuticals Inc., Neurophth Therapeutics Inc, Stoke Therapeutics Inc, Bionure Farma S.L., Mallinckrodt Pharmaceuticals, Ixchel Pharma LLC

Contents of the report:
1. Executive Summary
2. Optic Atrophy Management Market Report Structure
3. Optic Atrophy Management Market Trends And Strategies
4. Optic Atrophy Management Market - Macro Economic Scenario
5. Optic Atrophy Management Market Size And Growth
…..
27. Optic Atrophy Management Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.